

A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib

NCT07144111

| | |
|------------|-----------------|
| Status | RECRUITING |
| Phase | Phase 1 |
| Sponsor | Genentech, Inc. |
| Enrollment | 32 participants |

Key Eligibility Criteria

Inclusion (14)

- All participants:
- Body Mass Index 18.0 to 40.0 kilogram per meter square (kg/m^2), inclusive, and body weight ≥ 45 kg.
- Negative hepatitis B surface antigen (HBsAg) test
- Positive hepatitis B surface antibody (HBsAb) test or negative HBsAb
- Negative HIV (Human Immunodeficiency Virus) test

... and 9 more (see full listing online)

Exclusion (19)

- All participants:
- History of Type 1 diabetes or Type 2 Diabetes that is insulin-dependent or requires ongoing systemic treatment with two or more agents
- Significant history or clinical manifestation of any metabolic, allergic, dermatological, renal, hematological, pulmonary, cardiovascular, gastrointestinal (GI), neurological, or psychiatric disorder
- Significant illness, surgery, or hospitalization within 2 weeks prior to dosing.
- History of gastro-intestinal surgery

... and 14 more (see full listing online)

Locations (4 total)

Orange County Research Center, Lake Forest, California, United States

Orlando Clinical Research Center, Orlando, Florida, United States

The Texas Liver Institute, Inc., San Antonio, Texas, United States

... and 1 more locations